|
Third and successive–lines of chemotherapy in NSCLC patients without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón. |
|
Francisco Javier Afonso Afonso |
Consulting or Advisory Role - AstraZeneca Spain; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Takeda |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pfizer |
|
|
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Bayer; Boehringer Ingelheim; Ipsen; Merck; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer; Roche |
|
|
Consulting or Advisory Role - MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD Oncology; Roche/Genentech; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche |
Consulting or Advisory Role - Boehringer Ingelheim; Pierre Fabre |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; Novartis; Roche; ROVI |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Merck Sharp & Dome; PharmaMar |
|
Maria Carmen Areses Manrique |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Oncology; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Lilly; MSD; Novartis; Roche; Sanofi |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |